A First-In-Human Randomized, Double-Blind, Placebo-Controlled, Single- And Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 to Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

Antimicrobial Agents and Chemotherapy - United States

doi 10.1128/aac.03478-14